Reduced cyclic guanosine monophosphate (cGMP) concentration
Also known as: Reduced cGMP concentration · Verminderte cGMP-Konzentration · cGMP-Mangel · Decreased cyclic guanosine monophosphate · Low cGMP levels · …
Overview
What it is
This is a benign genetic variation, or polymorphism, that affects how a dog processes certain medications like sildenafil rather than causing a physical disease. It involves a change in the PDE5A gene, which is related to cellular signaling pathways. This variation does not cause any organ damage or clinical illness.
How it presents
Because this genetic variation is completely benign, affected dogs do not show any symptoms or health issues. There is no age of onset, and the dog's vision and general health remain entirely normal.
Treatment
No treatment or medical management is necessary for this condition. There are no associated healthcare costs, resulting in an expected lifetime cost of 0 EUR.
How it's tested
Affected breeds
Treatment cost
Estimated range of typical treatment cost. Actual cost depends on severity, clinic and region.
Frequently asked
What is Reduced cyclic guanosine monophosphate (cGMP) concentration?
This is a benign genetic variation, or polymorphism, that affects how a dog processes certain medications like sildenafil rather than causing a physical disease. It involves a change in the PDE5A gene, which is related to cellular signaling pathways. This variation does not cause any organ damage or clinical illness.
How is Reduced cyclic guanosine monophosphate (cGMP) concentration tested?
Various clinical and genetic tests are used depending on the breed and presentation.
Which breeds are most affected?
This condition isn't tied to a specific breed in our database.